Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Luminex and One Lambda have agreed to extend their 10-year strategic partnership to develop platforms and technologies for human leukocyte antigen (HLA) typing and antibody screening for the organ transplantation market.
Subscribe to our email newsletter
The partnership has resulted in the creation of new products that have made pre- and post-transplant diagnostics faster, and more cost-efficient.
One Lambda has adopted Luminex’s xMAP technology to create products that could reduce the cost and complexity of HLA typing and antibody screening.
The xMAP platform allows multiple, simultaneous tests to be run on a single sample, claims the company.
One Lambda president and CEO George Ayoub said one Lambda and Luminex combined the power of Luminex’s xMAP Technology with One Lambda’s expertise in HLA testing and organ transplantation to dramatically advance the care available to those undergoing transplants.
"Our platforms have significantly enhanced healthcare providers’ ability to care for organ transplant patients by delivering vital information that helps them to better match donors with recipients," Ayoub said.
The xMAP Technology platform has allowed One Lambda to analyse both nucleic acids and proteins to enhance and expand the company’s product menu and also to develop a range of assays that have streamlined transplant diagnostics.
One Lambda’s LABType SSO and LABScreen products can detect up to 500 HLA specificities in a single test, eliminating the need to run multiple tests.